Government funding for large randomised trials still needed to examine promise of new therapies

581

Jan Blankensteijn (Amsterdam, The Netherlands; principal investigator of the DREAM trial) tells Vascular News about what inspired him to design the DREAM trial, how its findings became particularly important with the long-term follow-up data for endovascular aneurysm repair (EVAR) and the current challenges encountered when undertaking randomised trials.

(Visited 223 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here